Update on the management of von Willebrand disease

Clinical Advances in Hematology and Oncology

Volumn 6, Issue 1, 2008, Pages 29-31

  Federici, Augusto B ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; DESMOPRESSIN; FANHDI; GLYCOPROTEIN IB; RECOMBINANT PROTEIN; RECOMBINANT VON WILLEBRAND FACTOR; RISTOCETIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; WILATE; ARGIPRESSIN[1 DEAMINO]; HEMOSTATIC AGENT;

ARTICLE; BLEEDING DISORDER; CLINICAL TRIAL; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HEMARTHROSIS; HEMATOMA; HEMOPHILIA; HEMOSTASIS; HUMAN; NONHUMAN; PROTEIN BLOOD LEVEL; THROMBOCYTE ADHESION; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE; DRUG COMBINATION; PATHOPHYSIOLOGY; REVIEW;

DEAMINO ARGININE VASOPRESSIN; DRUG COMBINATIONS; FACTOR VIII; HEMOSTATICS; HUMANS; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 41449110892     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Federici AB, Castaman G, Mannucci PM. Italian Association of Hemophilia Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia. 2002;8:607-621.
2. Federici AB, Canciani MT, Forza I, Cozzi G. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease: single center comparison of four different assays. Thromb Haemost, 2000;84:1127-1128.
3. Federici AB, Canciani MT, Forza I, et al. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibalpha for diagnosis of patients with low von Willebrand factor levels. Haematologica. 2004;89:77-85.
4. Sadler JE, Budde JU, Eikenboom JC, et al; The Working Party on von Willebrand Disease Classification. Update on the pathophysiology aqd classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4:2103-2014.
5. Federici AB, Mazurier G, Berntorp E, et al. Biological response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood. 2004;103:2032-2038.
6. Mannucci PM, Chediak J, Hanna W, et al. Alphanate Study Group. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood. 2002;99:450-456.
7. Federici AB, Castaman G, Franchini M, et al. Clinical use of Haemate-P in inherited von Willebrand disease: a cohort study on 100 Italian patients. Haematologica. 2007;92:944-955.
8. Borel-Derlon A, Federici AB, Roussel-Robert V, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand Factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost. 2007;5:1115-1124.
9. Federici AB, Bucciarelli P, Castaman G, et al. Incidence and determinants of bleeding in different typts of von Willebrand disease: results of the first prospective multicenter study on 814. Italian patients. Blood. 2007;100(11 pt 1): Abstract 713.